Moderna, Inc. (MRNA) Stock Valuation — PE Analysis
Biotechnology · NASDAQ
Current Price
$143.97
PE Ratio (TTM)
n/m
Intrinsic Value
Use the calculator below to estimate
COMPETITIVE MOAT
↑mRNA Platform Dominance
Moderna possesses a leading mRNA platform, enabling rapid vaccine and therapeutic development. This technological lead creates significant barriers to entry for competitors.
↑First-Mover Advantage
As a pioneer in mRNA vaccines, Moderna secured early market share and brand recognition. This established position is difficult for rivals to displace.
↑Strategic Partnerships
Collaborations with major pharmaceutical companies like Merck enhance Moderna's development pipeline and market access. These alliances leverage external expertise and resources.
INVESTMENT RISKS
↓Pipeline Concentration
Moderna's reliance on a few key mRNA candidates, particularly in oncology, presents a risk if these fail in late-stage trials. Diversification is crucial for long-term stability.
↓Regulatory Scrutiny
The biotechnology sector faces intense regulatory oversight. Any adverse findings or delays in approvals for new therapies could significantly impact Moderna's growth trajectory.
↓Competitive Landscape
While a leader, Moderna faces increasing competition from established players and emerging biotech firms in the mRNA space. Maintaining its edge requires continuous innovation and successful product launches.
Customize the MRNA PE valuation
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Moderna, Inc. respond.
Open PE Calculator for MRNACompany Overview
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Financial Metrics — MRNA PE Stock Valuation Data
PE Ratio (TTM)
n/m
PEG Ratio
2.14
Earnings Yield
-5.53%
ROE (TTM)
-39.2%
Revenue/Share (TTM)
$5.63
Debt/Equity
0.19x
Frequently Asked Questions
What is the PE ratio of MRNA?
The trailing twelve-month PE ratio of MRNA reflects how much investors pay per dollar of Moderna, Inc.'s earnings. This metric is most useful when compared to Biotechnology peers and the company's own historical range.
Is MRNA overvalued based on PE ratio?
MRNA's PE of -18.0x combined with a PEG ratio of 2.14 provides a growth-adjusted perspective. A PEG above 2.0 means the P/E is high relative to the earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Biotechnology, a DCF analysis may be more appropriate.
How do I value MRNA stock using PE ratio?
To value Moderna, Inc. using PE: (1) Compare the current PE (-18.0x) against the Biotechnology median to assess relative pricing, (2) check the PEG ratio (2.14) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
What is the PEG ratio of MRNA?
MRNA's PEG ratio is 2.14, calculated by dividing the PE ratio (-18.0x) by the expected earnings growth rate. A PEG above 2.0 means the P/E is high relative to the expected earnings growth rate. Note that PEG accuracy depends on the reliability of growth estimates.
Should I use PE ratio or DCF for MRNA stock valuation?
PE ratio gives a quick relative read — how MRNA is priced versus Biotechnology peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
Learn More
- See MRNA DCF Valuation → — Intrinsic value via Discounted Cash Flow analysis
- PE Methodology — Step-by-step guide to PE ratio stock valuation
- DCF Methodology — Guide to discounted cash flow analysis
- PE Ratio — Understanding the price-to-earnings ratio
- Intrinsic Value — How to evaluate stock fair value
Related PE Valuations
All Healthcare valuationsP/E and DCF value MRNA with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-09-11. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.